Open AccessEvaluation of the radioprotective properties of recombinant flagellin when used alone or in combination with interleukin-1 beta
Author(s) -
Elena V. Murzina,
Elena V. Murzina,
Г. А. Софронов,
Г. А. Софронов,
Simbirtsev As,
Simbirtsev As,
Natalia V. Aksenova,
Natalia V. Aksenova,
Olga M. Veselova,
Olga M. Veselova,
Alexander Ischenko,
А. М. Ищенко
Publication year - 2018
Publication title -
medicinskij akademičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2687-1378
pISSN - 1608-4101
DOI - 10.17816/maj18377-84
Subject(s) - flagellin , recombinant dna , medicine , interleukin , placebo , pharmacology , effective dose (radiation) , immunology , biology , nuclear medicine , pathology , cytokine , biochemistry , receptor , alternative medicine , gene
Research objective. To evaluate the radioprotective effectiveness of recombinant flagellin when used alone or in combination with interleukin-1 beta for prophylactic or therapeutic effect on animals. Materials and methods. The effect of hybrid flagellin FliC Salmonella typhimurium and human interleukin-1β (Institute of Highly Pure Biopreparations, Saint Petersburg, Russia) on the 30-day survival of male mice exposed to lethal doses of X-ray radiation was studied. Survival of irradiated animals was analyzed by Kaplan-Meier method. Results. The preventive use of flagellin had a protective effect on the 30-day survival of mice irradiated with lethal doses of X-rays. Compared with the irradiated control, the administration of flagellin (1 mg/kg or 2 mg/kg) prior to X-ray exposure (7.5 Gy, 8.0 Gy or 8.5 Gy) increased the animal survival rate to 67-87%. Complex preventive administration of flagellin (1 mg/kg) and interleukin-1 beta (50 μg/kg) provided a 100% survival rate of the irradiated mice. Separate use of drugs was also effective; 92.8% of mice survived when flagellin was administered prior to irradiation and interleukin after. Conclusion. Recombinant flagellin is a promising candidate product for designing new generation of domestic radiation countermeasures, including combinations with interleukin-1 beta.